CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Top Cited Papers
Open Access
- 12 February 2009
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 113 (7), 1581-1588
- https://doi.org/10.1182/blood-2008-07-168468
Abstract
Relapse of malignancy after allogeneic hematopoietic cell transplantation (allo-HCT) remains a therapeutic challenge. Blockade of the CTLA4 moleculeKeywords
This publication has 23 references indexed in Scilit:
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 2008
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningBlood, 2007
- Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?Frontiers in Bioscience-Landmark, 2007
- The Role of the CTLA4 Blockade in the Treatment of Malignant MelanomaCancer Investigation, 2007
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996